GleamWall
中文EN

ABUS Arbutus Biopharma Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1447028 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,142.6%
TTM net income YoY620.2%
TTM EPS YoY587.0%
Revenue 3-yr CAGR101.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin81.1%
Net margin121.2%
FCF margin—
EBITDA margin81.1%

Returns

ROE269.6%
ROA100.6%
ROIC (approx.)—
Asset turnover0.83x

Leverage & solvency

Liabilities / assets74.8%
Debt / equity0.00x
Current ratio1.40x
Interest coverage2,299.38x

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$299,000$1.01M$179.13M$1.05M$529,000$10.74M$1.76M$1.57M
R&D expense$2.62M$2.90M$4.12M$5.01M$5.78M$5.50M$8.96M$8.81M
SG&A expense$7.96M$3.87M$5.89M$3.69M$3.04M$3.33M$5.83M$4.71M
Operating income-$10.49M-$5.96M$168.91M-$5.29M-$8.66M$1.49M-$25.70M-$13.93M
Interest expense$11,000$18,000$17,000$18,000$23,000$28,000$28,000$30,000
Income tax$0$0$0—————
Net income$59.12M-$5.14M$169.69M-$3.76M-$7.74M$2.52M-$24.53M-$12.53M
EBITDA-$10.48M-$5.95M$168.92M-$5.28M-$8.65M$1.50M-$25.37M-$13.60M
EPS (basic)0.30-0.030.88—-0.040.01-0.13—
EPS (diluted)0.30-0.030.87—-0.040.01-0.13—
Weighted avg. shares (diluted)199.63M197.47M195.21M—191.78M192.40M190.71M—
Balance sheet
Cash & equivalents$264.19M$19.17M$23.71M$18.01M$22.41M$37.41M$37.08M$36.33M
Short-term investments$73.30M$73.45M$71.52M$73.46M$71.29M$60.68M$75.63M$86.29M
Receivables$792,000$369,000$1.31M$1.45M$905,000$1.02M$1.18M$2.41M
Current assets$339.57M$273.88M$277.01M$94.46M$97.44M$103.12M$116.81M$127.32M
PP&E, net$0$10,000$22,000$32,000$137,000$148,000$168,000$3.31M
Total assets$339.70M$274.02M$277.16M$94.62M$97.71M$103.27M$117.01M$131.71M
Current liabilities$241.93M$3.36M$5.11M$6.01M$5.18M$5.02M$19.43M$15.62M
Long-term debt$0$0$0$0$0$0$0$0
Total debt$0$0$0$0$0$0$0$0
Total liabilities$253.95M$15.29M$16.99M$18.04M$20.31M$20.29M$37.85M$34.34M
Shareholders' equity$85.75M$258.73M$260.18M$76.58M$77.40M$82.98M$79.16M$97.37M
Net debt-$264.19M-$19.17M-$23.71M-$18.01M-$22.41M-$37.41M-$37.08M-$36.33M
Shares outstanding199.28M197.63M196.95M192.53M191.95M191.64M191.48M189.96M
Cash flow statement
Operating cash flow$239.81M-$6.02M-$8.11M-$4.68M-$5.82M-$15.75M-$13.39M-$10.31M
Capital expenditure———$0$0$0$0$86,000
Free cash flow———-$4.68M-$5.82M-$15.75M-$13.39M-$10.40M
Investing cash flow$504,000-$1.66M$2.20M-$1.36M-$10.02M$15.61M$11.35M$13.41M
Financing cash flow$4.71M$3.15M$11.62M$1.64M$844,000$453,000$2.78M$1.42M
Depreciation & amortization$10,000$11,000$11,000$11,000$11,000$11,000$330,000$333,000
Stock-based compensation$1.16M$1.59M$1.36M$1.26M$1.20M$764,000$3.56M$1.63M

Free plan shows the latest 8 periods; Pro shows all 55 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.